| Today’s Big NewsOct 3, 2023 |
| By Zoey Becker An FDA advisory committee is set to determine if the trial was adequate and well-controlled as the agency weighs a potential full approval for Amgen's KRAS inhibitor. |
|
|
|
By Gabrielle Masson Eli Lilly is snapping up Point Biopharma Global, acquiring the radiopharmaceutical cancer company for $1.4 billion and entrance into the therapeutic space. |
By Conor Hale According to the report, the Swiss Big Pharma is in the early stages of shopping around for a buyer of part of its Advanced Accelerator Applications portfolio. |
By Zoey Becker After reaching deals with various buyers, Viatris is pulling out of women's health and selling most of its over-the-counter products. It's also offloading the active pharmaceutical ingredient business in India. With the deals, the company will transfer 10 manufacturing sites and around 6,000 employees to the new owners. |
|
Thursday, October 12, 2023 | 11am ET / 8am PT A fundamental research question continues to resonate today: How can we proactively develop countermeasures against future viral outbreaks? In this webinar, leaders in industry and academia discuss their experiences using innovative tools to study and develop therapeutics against influenza, SARS-CoV-2, dengue viruses, and more. Register now. 
|
|
By Nick Paul Taylor As Johnson & Johnson retreats from the vaccine sector, Sanofi is gambling $175 million on the healthcare giant's late-phase E. coli vaccine. |
By Conor Hale The FDA has granted a pair of de novo clearances to ProciseDx for the agency’s first rapid tests to measure the levels of specific biologic drugs within a patient’s bloodstream—allowing clinicians to quickly dial in personalized doses. |
By Kevin Dunleavy Despite patent expirations which will weigh heavy later in the decade, the pharma industry is on course for solid growth in both sales and earnings, according to analysts at TD Cowen. |
By Max Bayer 2023 has been a banner year for San Diego-based siRNA biotech ADARx, with two assets jumping to the clinic. Next year could be even bigger. |
By Zoey Becker The agency spotted issues relating to chemistry, manufacturing and controls (CMC) processes in the company's application for its liquid botulinum toxin type A. |
By Andrea Park A tablet-based app could help reduce disparities in autism spectrum disorder diagnoses across gender, race and ethnicity, according to a new study funded by the NIH. |
By Annalee Armstrong Intellia and Regeneron hope to take their CRISPR partnership outside the liver with an expansion on their existing work that yielded first-in-human gene-editing data in 2021. |
Fierce podcasts Don’t miss an episode |
| In this episode of "The Top Line," Fierce Pharma's Eric Sagonowksy talks with Pam Cheng, the AstraZeneca executive who is playing a key role in driving the company's sustainability ambitions. |
|
|---|
|
|
|
Thursday, October 12, 2023 | 2pm ET / 11am PT In this webinar, we take a deep dive into different strategies for unifying enterprise-wide lab data. You'll learn how to drive better access, collaboration, and AI-driven insight. Don't miss out, register today. 
|
|
Webinar Embark on an in-depth journey through the pivotal Make-Test-Decide Workflow, where collaboration and data-driven decisions play a paramount role in the intricate landscape of drug discovery. Watch now to learn how cloud implementation fosters accessibility and collaboration, revolutionizing research across locations and companies. Sponsored by: Revvity Signals |
eBook Learn how to get better results from suboptimal biospecimens for NGS and protein analysis. Sponsored by: Covaris |
Whitepaper Economic and regulatory factors are making biopharma supply chains more complex in the EU. This paper explores strategies that biopharma companies can use to better manage complexity, cost, and risk. Presented by: AIM, the supply chain leader for life science entrants and midsize life science companies |
Whitepaper From Assay Development Through Large Molecule Development. Streamline your R&D workflows and gain valuable insights with our Biology Solutions Brochure. Download now to discover how to control your laboratory workflows across various assay techniques, modalities, and data types. Sponsored by: Revvity Signals |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
Whitepaper Learn how outsourcing the buffer preparation can reallocate resources to support core activities of your bioprocess production. Sponsored by: Thermo Fisher Scientific |
Whitepaper From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
Whitepaper By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
| |
|
